1. In Vivo
  2. >>Archive

GSK's Virtual-Proof-of-Concept Unit in Tune with Lilly's Chorus

Many readers will have heard of Eli Lilly's Chorus initiative, designed to drive compounds through to proof-of-concept as cheaply and quickly as possible. A less well-publicized but similar discovery-on-a-budget initiative is GlaxoSmithKline's VPoC--virtual-proof-of-concept--unit.

Many readers will have heard of Eli Lilly & Co.'s Chorus initiative, designed to drive compounds through to proof-of-concept as cheaply and quickly as possible. ( See "Lilly Tries to Buy Time," this issue Also see "Lilly Tries to Buy Time" - In Vivo, 1 December, 2009.and " Lilly's Chorus Experiment," IN VIVO , May 2007 Also see "Lilly's Chorus Experiment" - In Vivo, 1 May, 2007..) Less well-publicized is GlaxoSmithKline PLC's development-on-a-budget initiative, known as the VPoC, or virtual proof-of-concept.

The six-person operation, conceived and run by SVP, Molecular Discovery Allen Oliff, MD, is actually a drug performance unit (DPU),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

Sponsored by:

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

ADC Innovation: Record Funding Fuels Tubulis’s Clinical Push Into 2026

 
• By Lucie Ellis-Taitt

“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.

Deals In Depth: October 2025

 
• By Maureen Riordan and Deanna Kamienski

Eleven $1bn+ alliances were penned in October, and four exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $11.4bn collaboration with Takeda to co-develop and commercialize next-generation immuno-oncology and antibody-drug conjugate cancer therapies.

Clinical Trial Roundup: Oncology Dominates, Cardiovascular Surges, Infectious Disease Declines

 
• By Shannon Fisher and Heidi Chen

In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.